Haptoglobin 1-1 genotype is associated with poorer cognitive functioning in the elderly with type 2 diabetes

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3139-3145

  Ravona Springer, Ramit ^a   Heymann, Anthony ^b   Schmeidler, James ^c   Guerrero Berroa, Elizabeth ^c   Sano, Mary ^c   Preiss, Rachel ^d   Koifman, Keren ^a   Hoffman, Hadas ^d   Levy, Andrew ^e   Silverman, Jeremy M ^c   Schnaider Beeri, Michal ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MACCABI HEALTHCARE SERVICES   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HAPTOGLOBIN;

AGED; ARTICLE; ATTENTION; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; SEMANTIC MEMORY; WORKING MEMORY;

COGNITION; DIABETES MELLITUS, TYPE 2; GENOTYPE; HAPTOGLOBINS; HUMANS; RISK FACTORS;

EID: 84891885091     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2250     Document Type: Article

References (44)

1. Thomas VS, Darvesh S, MacKnight C, Rockwood K. Estimating the prevalence of dementia in elderly people: a comparison of the Canadian Study of Health and Aging and National Population Health Survey approaches. Int Psychogeriatr 2001;13 (Suppl. 1):169-175
2. Cavalieri M, Ropele S, Petrovic K, et al. Metabolic syndrome, brain magnetic resonance imaging, and cognition. Diabetes Care 2010;33:2489-2495
3. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007;64:570-575
4. Schnaider BeeriM, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004;63:1902-1907
5. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010;75: 1195-1202
6. Peila R, Rodriguez BL, Launer LJ;Honolulu- Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002;51:1256-1262
7. Costacou T, Ferrell RE, Ellis D, Orchard TJ. Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes 2009; 58:2904-2909
8. Levy AP, Hochberg I, Jablonski K, et al.; Strong Heart Study. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol 2002;40:1984-1990
9. Levy AP, Gerstein HC,Miller-Lotan R, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004;27:2767
10. Roguin A, KochW, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care 2003;26:2628-2631
11. Suleiman M, Kapeliovich MR, Roguin A, et al. Haptoglobin type and 30-day mortality in diabetic individuals presenting with acutemyocardial infarction. Diabetes Care 2003;26:2699-2700
12. Lioupis C, Barbatis C, Drougou A, et al. Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques. Atherosclerosis 2011;216: 131-138
13. Bowman BH, Kurosky A. Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet 1982;12:189-261, 453-454
14. Bamm VV, Tsemakhovich VA, Shaklai M, Shaklai N. Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry 2004;43:3899-3906
15. Vardi M, Levy AP. Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes? Curr Diab Rep 2012;12:274-279
16. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996; 42:1589-1600
17. Asleh R, Blum S, Kalet-Litman S, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008;57: 2794-2800
18. Staals J, Pieters BM, Knottnerus IL, et al. Haptoglobin polymorphism and lacunar stroke. Curr Neurovasc Res 2008;5:153-158
19. Staals J, Henskens LH, Delanghe JR, et al. Haptoglobin phenotype correlates with the extent of cerebral deep white matter lesions in hypertensive patients. Curr Neurovasc Res 2010;7:1-5
20. Heymann AD, Chodick G, Halkin H, et al. The implementation of managed care for diabetes using medical informatics in a large Preferred Provider Organization. Diabetes Res Clin Pract 2006;71:290-298
21. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183-194
22. Fillenbaum GG, Peterson B, Morris JC. Estimating the validity of the clinical Dementia Rating Scale: the CERAD experience. Consortiumto Establish a Registry for Alzheimer's Disease. Aging (Milano) 1996; 8:379-385
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189-198
24. Beeri MS, Schmeidler J, SanoM, et al. Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old. Neurology 2006;67:1006-1010
25. Fernaeus SE, Almkvist O. Word production: dissociation of two retrieval modes of semantic memory across time. J Clin Exp Neuropsychol 1998;20:137-143
26. SpreenO, Benton AL. Neurosensory Center Comprehensive Examination for Aphasia: Manual of instructions (NCCEA). Rev. ed. Victoria, BC, University of Victoria, 1977
27. Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual. San Antonio, The Psychological Corporation, 1981
28. Wechsler D. Wechsler Memory Scale- Revised Manual. San Antonio, The Psychological Corporation, 1987
29. American Psychiatric Association, Ed. Diagnostic and Statistical Manual of Mental Disorders IV. Washington, DC, American Psychiatric Association, 2010
30. Koch W, Latz W, Eichinger M, et al. Genotyping of the common haptoglobin Hp 1/2 polymorphismbased on PCR. Clin Chem 2002;48:1377-1382
31. Olkin I, Finn JD. Correlations redux. Psychol Bull 1995;118:155-164
32. Anderson GD, Temkin NR, Dikmen SS, et al. Haptoglobin phenotype and apolipoprotein E polymorphism: relationship to posttraumatic seizures and neuropsychological functioning after traumatic brain injury. Epilepsy Behav 2009;16:501-506
33. Wang S, Jacobs D, Andrews H, et al. Cardiovascular risk and memory in nondemented elderly women. Neurobiol Aging 2010;31:1250-1253
34. Jokinen H, Gouw AA, Madureira S, et al.; LADIS Study Group. Incident lacunes influence cognitive decline: the LADIS study. Neurology 2011;76:1872-1878
35. Rouhl RP, van Oostenbrugge RJ, Damoiseaux JG, et al. Haptoglobin phenotype may alter endothelial progenitor cell cluster formation in cerebral small vessel disease. Curr Neurovasc Res 2009; 6:32-41
36. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993;91:977-985
37. Shah NS, Vidal JS, Masaki K, et al. Midlife blood pressure, plasma b-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension 2012;59: 780-786
38. EngströmG, Lind P,Hedblad B, Stavenow L, Janzon L, Lindgärde F. Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 2002;33:2744-2749
39. Van Vlierberghe H, Langlois M, Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta 2004;345:35-42
40. HennemanWJ, Sluimer JD, Barnes J, et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009;72:999-1007
41. Spauwen PJ, Köhler S, Verhey FR, Stehouwer CD, van Boxtel MP. Effects of type 2 diabetes on 12-year cognitive change: results from the Maastricht Aging Study. Diabetes Care 2013;36:1554-1561
42. Pedersen M, Pedersen KK, Bruunsgaard H, et al. Cognitive functions in middle aged individuals are related to metabolic disturbances and aerobic capacity: a cross-sectional study. PLoS ONE 2012;7: e51132
43. Okereke OI, Kang JH, Cook NR, et al. Type 2 diabetes mellitus and cognitive decline in two large cohorts of communitydwelling older adults. J Am Geriatr Soc 2008;56:1028-1036
44. Levy AP, Asleh R, Blum S, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010;12:293-304